CSF2 and pancreatic neoplasm: A pilot study further illustrated that an allogeneic GM-CSF secreting pancreatic cancer cells vaccine could stimulate MSLN specific T cells and that was favourable in gemcitabine-resistant advanced pancreatic cancer patients.